Amgen’s $10.4 billion offer for South San Francisco-based Onyx Pharmaceuticals signals a new finance-oriented era of dealmaking under CEO and former investment banker Robert Bradway. Thousand Oaks-based Amgen, the world’s biggest biotechnology company, said Aug. 26 that it plans to offer $125 per share for Onyx, whose crown jewel is a recently approved blood cancer…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
